首页|期刊导航|iLIVER|Advancing hepatology through innovation and integration:iLIVER''s vision for 2026

Advancing hepatology through innovation and integration:iLIVER''s vision for 2026OA

中文摘要

Liver diseases continue to impose a substantial and evolving burden on global health up to 2026,characterised by a wide clinical spectrum and increasing therapeutic complexity.Liver cancer remains the sixth most common malignancy and the third leading cause of cancer-related mortality worldwide,with hepatocellular carcinoma(HCC)accounting for nearly 75%of all primary liver cancers.1 Although sustained viral hepatitis control programs have stabilized or reduced virus-related HCC incidence in many regions,its epidemiological profile is undergoing a marked transition,with metabolic dysfunction-associated steatotic liver disease(MASLD)increasingly contributing to HCC cases,driven by global obesity and metabolic syndrome epidemics.

Zu-Chao Du;Ke-Chun Wang;Ming-Da Wang;Lei Cai;Jian-Hong Zhong;Tian Yang

Department of Hepatobiliary Surgery,The First Affiliated Hospital,Henan University,Kaifeng 475000,Henan,ChinaDepartment of Hepatobiliary Surgery,Eastern Hepatobiliary Surgery Hospital,Naval Medical University,Shanghai 200438,ChinaDepartment of Hepatobiliary Surgery,Eastern Hepatobiliary Surgery Hospital,Naval Medical University,Shanghai 200438,ChinaInstitute of Hepatopancreatobiliary Surgery,Chongqing General Hospital,Chongqing University,Chongqing 401147,ChinaDepartment of Hepatobiliary Surgery,Affiliated Tumor Hospital of Guangxi Medical University,Nanning 530021,Guangxi,ChinaDepartment of Hepatobiliary Surgery,Eastern Hepatobiliary Surgery Hospital,Naval Medical University,Shanghai 200438,China

医药卫生

Hepatocellular carcinomaArtificial intelligenceLiquid biopsyConversion therapyMetabolic dysfunction-associated steatotic liver diseasePrecision medicine

《iLIVER》 2026 (1)

P.1-3,3

10.1016/j.iliver.2026.100224

评论